ACTICCA-1

ACTICCA-1 is an international multi centre trial, and is currently open in a few locations in the UK, and planned to open in 20+.

For more details, see:

https://www.ukctg.nihr.ac.uk/ and search for:  ACTICCA-1
and:
https://clinicaltrials.gov/ct2/show/NCT02170090

Lead investigator on the ACTICCA-1 trial in the UK:
Professor John Bridgewater
Medical Oncologist, University College Hospital London

Tel: 020 3447 9093
Fax: 020 3447 9055
Email: j.bridgewater@ucl.ac.uk

UCL Cancer Institute
72 Huntley Street
London   WC1E 6AA

18.05.17  In the light of the BILCAP study result, this trial is no longer recruiting.  If you are currently in the trial, please contact your consultant for advice on your choices. 

For more information on the BILCAP result, please go to:  http://ammf.org.uk/2017/05/18/bilcap-results-show-chemo-improves-survival

In this video Dr John Marshall of Georgetown University, and Professor John Primrose of the University of Southampton, discuss the practice-changing findings of the BILCAP study which investigated adjuvant capecitabine for biliary tract cancer (cholangiocarcinoma).  The pan-European study that Professor Primrose refers to (6:09 into the interview) is the ACTICCA-1 trial.


 

Back to previous page